Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, at 10:30 am ET. The event will include a Respiratory/Infections Corporate Panel Discussion.

The conference will be accessible via webcast on Theravance.com, where a replay will be available for 30 days. Theravance Biopharma is known for its FDA-approved YUPELRI® inhalation solution for COPD and is developing Ampreloxetine, targeting neurogenic orthostatic hypotension. The firm's commitment is towards improving patient lives and increasing shareholder value.

DUBLIN, March 2, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the 43^rd Annual TD Cowen Health Care Conference on Wednesday, March 8 at 10:30 am ET (7:30 am PT/3:30 pm GMT).

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in multiple symptom atrophy patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301760481.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma participate in the TD Cowen Health Care Conference?

Theravance Biopharma will participate in the TD Cowen Health Care Conference on March 8, 2023, at 10:30 am ET.

What is the focus of Theravance Biopharma at the upcoming conference?

Theravance Biopharma will focus on the Respiratory/Infections Corporate Panel Discussion at the conference.

How can I access the webcast of the Theravance Biopharma conference presentation?

The webcast can be accessed at Theravance.com under the Investors section, Presentations and Events.

What are the major products of Theravance Biopharma?

Theravance Biopharma's major products include YUPELRI® for COPD and Ampreloxetine for neurogenic orthostatic hypotension.

How long will the replay of the Theravance Biopharma conference be available?

The replay of the webcast will be available for 30 days after the event.